• Profile
Close

Once-weekly efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to liraglutide

Diabetes Care Jul 24, 2019

Rosenstock J, et al. - In early type 2 diabetes (T2D) (drug naive or on metformin monotherapy), researchers tested once-weekly efpeglenatide, a long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA) for its effectiveness, safety, and tolerability. For this analysis, patients, of whom ∼90% were on metformin monotherapy, were randomized to 1 of 5 efpeglenatide doses (0.3, 1, 2, 3, or 4 mg QW; n=181), placebo (n=37), or liraglutide (≤1.8 mg daily; n=36). According to findings, once a week, ephpeglenatide resulted in significant decreases in HbA1c and weight. The safety profile was consistent with the GLP-1 RA class in patients with early T2D primarily under metformin monotherapy. With efpeglenatide, no neutralizing antibodies were identified.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay